ErVimmune uses a proprietary AI‑driven platform to identify shared, non‑mutated tumor epitopes derived from human endogenous retroviruses (HERVs) and validates them with proteomics and immunology assays. These epitopes are incorporated into therapeutic cancer vaccines and T‑cell‑based products designed to elicit high‑avidity cytotoxic responses in immunologically “cold” tumors such as triple‑negative breast cancer, ovarian cancer, sarcoma, glioblastoma, and acute myeloid leukemia.
Funding
$23.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cold, low‑mutational‑burden tumors such as triple‑negative breast cancer, ovarian cancer, sarcoma, glioblastoma and acute myeloid leukemia respond poorly to existing checkpoint‑inhibitor immunotherapies, leaving patients with limited treatment options.
Solution
ErVimmune leverages a proprietary, AI‑driven platform to discover shared, non‑mutated tumor epitopes derived from human endogenous retroviruses (HERVs). These epitopes are validated through proteomics and immunology assays and incorporated into therapeutic cancer vaccines and T‑cell‑based therapies. By targeting antigens that are commonly expressed across patients, the approach aims to generate high‑avidity cytotoxic T‑cell responses even in immunologically “cold” tumors. The company advances multiple pre‑clinical candidates, with the first vaccine slated for a clinical trial in triple‑negative breast cancer. ErVimmune’s pipeline also includes TCR‑engineered T‑cell products that can be combined with vaccines for durable tumor control.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical research organizations developing immunotherapies for cold tumors, as well as oncologists seeking novel treatment options for patients with low‑mutational‑burden cancers.
Features
- AI‑powered bioinformatics pipeline that identifies shared HERV‑derived epitopes across tumor types
- Proteomics‑based validation of epitope expression and immunogenicity
- Therapeutic vaccine platform designed to elicit high‑avidity cytotoxic T‑cell responses
- TCR‑engineered T‑cell therapy targeting the same HERV antigens for synergistic treatment
- Focus on low‑mutational‑burden (“cold”) solid tumors and hematologic malignancies where checkpoint inhibitors are ineffective
- Pre‑clinical portfolio of nine projects, with two candidates in late pre‑clinical development